NCT07934927
A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal Melanoma
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Objective Response Rate (ORR: CR+PR)
Timeframe: up to 18 weeks
Secondary (3)
AEs+SAEs
overall survival(OS)
progress-free survival(RFS)
Arms and interventions
Assigned InterventionsExperimental
Drug: Nab-paclitaxel Injection Nab-paclitaxel 200 mg/m² IV infusion Q3W Drug: Retlirafusp Alfa Injection Retlirafusp Alfa 1 diluted in 250 mL normal saline IV, administered 30 minutes before chemotherapy, Q3W Drug: Apatinib Mesylate Tablet Apatinib Mesylate 250 mg PO QD Regimen: Nab-paclitaxel + Retlirafusp Alfa + Apatinib Mesylate, Q3W × 6 cycles (combination phase); maintenance: Apatinib Mesylate + Retlirafusp Alfa until disease progression or unacceptable toxicity
Drugs: Retlirafusp Alfa Injection
Sites
1 site in 1 country
- Sun yat-sen uniersityGuangzhou, Guangdong, China